Inhibition of Fibrosis and Inflammation by Triple Therapy with Pirfenidone, Edaravone, and Erythropoietin in Rabbits with Drug-Induced Lung Injury : Computed Tomography-Pathological Correlation

吡非尼酮、依达拉奉和促红细胞生成素三联疗法对药物性肺损伤家兔纤维化和炎症的抑制作用：计算机断层扫描-病理相关性

• 批准号: 22791185
• 负责人: WATANABE Shobu
• 金额: $ 2.08万
• 依托单位: Shiga University of Medical Science
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Young Scientists (B)
• 财政年份: 2010
• 资助国家: 日本
• 起止时间: 2010 至 2011
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-22791185/
• 关键词: 薬剤性肺障害; ブレオマイシン; ピルフェニドロン; エダラボン; エリスロポイエチン; 薬剤性肺傷害; アシアロエリスロポエチン; 医療・福祉; 放射線; 病理学

We divided drug-induced lung injury rabbits into 3groups ; the control group(G1), pirfenidone group(G2), and a three-drug combination group(G3)(pirfenidone, edaravone, and erythropoietin). CT on day 28, G3 tended to exhibit a smaller area with abnormal opacity compared with G1(p=0. 071). In microscopic specimens, the average fibrosis score showed a significant difference between G1 and G3(p<0. 05). Moreover, the average fibrosis score tended to be smaller in G3 than in G2(p<0. 1).From the above, administration of pirfenidone alone suppressed the advancement of drug-induced lung injury, but the three-drug combination prevented further progression.

将药物性肺损伤兔分为对照组(G1)、吡非尼酮组(G2)和三联用药组(G3)(吡非尼酮、依达拉奉、促红细胞生成素)。28天时，G3的CT表现为面积较小，呈异常混浊，与G1相比有统计学意义(p=0。071)。在显微镜标本中，G1组和G3组的平均纤维化评分有显著差异(p&lt；0。05)。此外，G3组的平均纤维化评分往往小于G2组(p&lt；0。1)综上所述，单用吡非尼酮可抑制药物性肺损伤的进展，但三药合用可阻止进一步的进展。